Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.
作者信息
Gianfrancesco Milena A, Hyrich Kimme L, Gossec Laure, Strangfeld Anja, Carmona Loreto, Mateus Elsa F, Sufka Paul, Grainger Rebecca, Wallace Zachary, Bhana Suleman, Sirotich Emily, Liew Jean, Hausmann Jonathan S, Costello Wendy, Robinson Philip, Machado Pedro M, Yazdany Jinoos
机构信息
Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, 94143 CA, USA.
Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
出版信息
Lancet Rheumatol. 2020 May;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3. Epub 2020 Apr 16.
Abstract
摘要
相似文献
1
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.风湿性疾病与2019冠状病毒病：来自2019冠状病毒病全球风湿病联盟医疗服务提供者登记处的初步数据。
Lancet Rheumatol. 2020 May;2(5):e250-e253. doi: 10.1016/S2665-9913(20)30095-3. Epub 2020 Apr 16.
2
Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.抗击新冠疫情需要您的帮助：请为新冠全球风湿病联盟登记处做出贡献。
Int J Rheum Dis. 2020 Dec;23(12):1744. doi: 10.1111/1756-185X.14038.
3
Initial data from the COVID-19 Global Rheumatology Alliance provider registries.来自新冠全球风湿病联盟提供者登记处的初始数据。
Lancet Rheumatol. 2020 Jun;2(6):e317. doi: 10.1016/S2665-9913(20)30124-7. Epub 2020 May 5.
4
Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authors' reply.来自COVID-19全球风湿病联盟提供者登记处的初始数据——作者回复。
Lancet Rheumatol. 2020 Jun;2(6):e317. doi: 10.1016/S2665-9913(20)30125-9. Epub 2020 May 5.
5
COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19).意大利风湿病学 COVID-19 ：意大利风湿病学会（CONTROL-19）意大利登记处的初步结果。
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28.
6
The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance.风湿病学界对COVID-19大流行的应对：COVID-19全球风湿病联盟的成立。
Rheumatology (Oxford). 2020 Jun 1;59(6):1204-1206. doi: 10.1093/rheumatology/keaa191.
7
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.管理 COVID-19 大流行期间的风湿性疾病患者：法国风湿病学会回答了截至 2020 年 5 月最常被问到的问题。
Joint Bone Spine. 2020 Oct;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006. Epub 2020 May 27.
8
Longitudinal analysis of a pediatric rheumatology clinic population.一家儿科风湿病诊所人群的纵向分析。
J Rheumatol. 2005 Oct;32(10):1992-2001.
9
Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.抗击新冠疫情需要您的帮助：请为新冠全球风湿病联盟登记处做出贡献。
Int J Rheum Dis. 2020 Nov;23(11):1606. doi: 10.1111/1756-185X.14026.
10
Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.抗击新冠疫情需要您的帮助：请为新冠全球风湿病联盟注册库做出贡献。
Int J Rheum Dis. 2020 Sep;23(9):1262. doi: 10.1111/1756-185X.13967.
引用本文的文献
1
Exploring the complex relationship between systemic lupus erythematosus and coronavirus disease 2019: genetic insights and potential protective mechanisms.探索系统性红斑狼疮与2019冠状病毒病之间的复杂关系：遗传学见解与潜在保护机制。
J Glob Health. 2025 Jul 11;15:04191. doi: 10.7189/jogh.15.04191.
2
Early combined therapy for COVID-19 in immunocompromised patients: a promising approach against viral persistence and drug resistance.免疫功能低下患者COVID-19的早期联合治疗：对抗病毒持续存在和耐药性的一种有前景的方法。
BMC Infect Dis. 2025 Apr 28;25(1):616. doi: 10.1186/s12879-025-11012-3.
3
Outcome of COVID-19 in patients with idiopathic inflammatory myopathy during the Omicron wave in China: A longitudinal observational study.中国奥密克戎毒株流行期间特发性炎性肌病患者的新冠病毒病结局：一项纵向观察性研究
PLoS One. 2025 Feb 10;20(2):e0317319. doi: 10.1371/journal.pone.0317319. eCollection 2025.
4
Clinical characteristics of SARS-CoV-2 Omicron pneumonia in immunocompromised and immunocompetent patients: A retrospective cohort study.免疫功能低下和免疫功能正常患者的新型冠状病毒奥密克戎肺炎临床特征：一项回顾性队列研究
Heliyon. 2024 Oct 9;10(20):e39044. doi: 10.1016/j.heliyon.2024.e39044. eCollection 2024 Oct 30.
5
Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls.儿童自身免疫性炎症性风湿病患者和对照者对抗 SARS-CoV-2 BNT162b2 mRNA 疫苗的细胞免疫反应。
Clin Exp Immunol. 2024 Jul 12;217(2):167-172. doi: 10.1093/cei/uxae044.
6
The effect of COVID-19 infection on patients with rheumatic diseases in China.新型冠状病毒肺炎疫情对中国风湿病患者的影响。
Clin Rheumatol. 2024 Mar;43(3):1199-1206. doi: 10.1007/s10067-023-06825-z. Epub 2024 Jan 29.
7
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.新冠疫情及疫苗接种运动对大流行头三年中1755例系统性硬化症患者的影响。在下一疫情阶段，免疫反应受损者、正在接受免疫调节治疗者以及患有疾病相关肺部病变者面临的潜在风险。
J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec.
8
COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology.COVID-19 预后在系统性红斑狼疮与类风湿关节炎和脊柱关节炎中的比较：来自意大利风湿病学会的 CONTROL-19 研究的结果。
Lupus Sci Med. 2023 Oct;10(2). doi: 10.1136/lupus-2023-000945.
9
Clinical course, chest computed tomography severity score and outcome of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases.风湿性疾病患者中2019冠状病毒病（COVID-19）的临床病程、胸部计算机断层扫描严重程度评分及预后
Egypt Rheumatol. 2022 Jun;44(3):245-250. doi: 10.1016/j.ejr.2021.12.010. Epub 2022 Jan 5.
10
Clinical course and prognostic factors of COVID-19 infection in patients with chronic inflammatory-rheumatic disease: A retrospective, case-control study.慢性炎症性风湿性疾病患者感染新型冠状病毒肺炎的临床病程及预后因素：一项回顾性病例对照研究
Arch Rheumatol. 2022 Sep 20;38(1):44-55. doi: 10.46497/ArchRheumatol.2023.9289. eCollection 2023 Mar.
本文引用的文献
1
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.仓促下结论？有关羟氯喹治疗 COVID-19 的快速报告和结果传播及其后果。
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
2
COVID-19 infection and rheumatoid arthritis: Faraway, so close!COVID-19 感染与类风湿关节炎：远在天边，近在咫尺！
Autoimmun Rev. 2020 May;19(5):102523. doi: 10.1016/j.autrev.2020.102523. Epub 2020 Mar 20.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Biologics registers in RA: methodological aspects, current role and future applications.类风湿关节炎生物制剂注册：方法学方面、当前作用和未来应用。
Nat Rev Rheumatol. 2017 Aug;13(8):503-510. doi: 10.1038/nrrheum.2017.81. Epub 2017 Jun 1.
5
Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.类风湿关节炎的生物疗法与机会性感染的风险：一项荟萃分析。
Clin Infect Dis. 2014 Jun;58(12):1649-57. doi: 10.1093/cid/ciu185. Epub 2014 Mar 18.
6
Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.类风湿关节炎的感染和生物治疗：我们对风险和预防的认识不断变化。
Rheum Dis Clin North Am. 2012 Nov;38(4):727-45. doi: 10.1016/j.rdc.2012.08.019. Epub 2012 Sep 30.
7
The risk of infections with biologic therapies for rheumatoid arthritis.类风湿关节炎生物治疗的感染风险。
Semin Arthritis Rheum. 2010 Apr;39(5):327-46. doi: 10.1016/j.semarthrit.2008.10.002. Epub 2008 Dec 31.
8
Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome.系统性红斑狼疮中的带状疱疹感染：危险因素及预后
J Rheumatol. 1994 Jan;21(1):84-6.
Zotero 插件